Verona Pharma plc financial data

Symbol
VRNA on Nasdaq
Industry
Pharmaceutical Preparations
Location
3 More London Riverside, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.55K % +25.5%
Debt-to-equity 46.2 % +227%
Return On Equity -55.4 % -173%
Return On Assets -37.9 % -113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 650M shares +2.2%
Common Stock, Shares, Outstanding 649M shares +2.02%
Entity Public Float 1.5B USD +607%
Common Stock, Value, Issued 42.8M USD +2.44%
Weighted Average Number of Shares Outstanding, Basic 648M shares +2.17%
Weighted Average Number of Shares Outstanding, Diluted 648M shares +2.17%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Research and Development Expense 44.3M USD -47%
General and Administrative Expense 97.8M USD +174%
Operating Income (Loss) -131M USD -110%
Nonoperating Income (Expense) 7.34M USD -34.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -124M USD -142%
Income Tax Expense (Benefit) 1.76M USD +206%
Net Income (Loss) Attributable to Parent -125M USD -143%
Earnings Per Share, Basic -0.2 USD/shares -150%
Earnings Per Share, Diluted -0.2 USD/shares -150%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 405M USD +49.4%
Other Assets, Current 2.58M USD -57.5%
Assets, Current 416M USD +44.6%
Property, Plant and Equipment, Net 44K USD +300%
Operating Lease, Right-of-Use Asset 2.24M USD +314%
Goodwill 545K USD 0%
Assets 434M USD +42.8%
Accounts Payable, Current 4.15M USD +66.5%
Employee-related Liabilities, Current 3.96M USD +59.8%
Accrued Liabilities, Current 19.6M USD +163%
Contract with Customer, Liability, Current 21.3M USD
Liabilities, Current 48.3M USD +342%
Operating Lease, Liability, Noncurrent 1.48M USD +4827%
Liabilities 266M USD +762%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.6M USD 0%
Retained Earnings (Accumulated Deficit) -485M USD -35.1%
Stockholders' Equity Attributable to Parent 168M USD -38.4%
Liabilities and Equity 434M USD +42.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.6M USD -135%
Net Cash Provided by (Used in) Financing Activities -3.12M USD -105%
Net Cash Provided by (Used in) Investing Activities -16K USD
Common Stock, Shares, Issued 668M shares +2.46%
Common Stock, Par or Stated Value Per Share 0.05 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.9M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 405M USD +49.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 933K USD +282%
Deferred Tax Assets, Valuation Allowance 55.5M USD +14.5%
Deferred Tax Assets, Gross 109M USD +31.7%
Operating Lease, Liability 2.96M USD +236%
Payments to Acquire Property, Plant, and Equipment 16K USD
Lessee, Operating Lease, Liability, to be Paid 3.59M USD +296%
Operating Lease, Liability, Current 1.03M USD +89.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 842K USD +292%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +74.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 634K USD +2248%
Lessee, Operating Lease, Liability, to be Paid, Year Three 788K USD +4535%
Deferred Tax Assets, Operating Loss Carryforwards 54M USD +38.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 784K USD
Additional Paid in Capital 617M USD +3.45%
Depreciation, Depletion and Amortization 263K USD +67.5%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 29.5M USD +76.8%
Interest Expense 4.37M USD +217%